Mafloxin

Quick links to important sections

Mafloxin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mafloxin

Quick Facts

Property Description
Active Ingredient Marbofloxacin
Form Oral Tablets and Injectable Aqueous Solution
Pharmacological Class Fluoroquinolone Antibiotic
General Purpose To eliminate bacterial infections
Origin Synthetic (Chemically Synthesized)

What Type of Medicine is Mafloxin?

Mafloxin is a prescription-only antibacterial agent containing the active ingredient Marbofloxacin, which is recognized within the medical community as a potent, synthetic compound. It is specifically classified as a fluoroquinolone antibiotic, belonging to the broader class of anti-infective medications. This drug is often utilized when addressing infections caused by Gram-positive and Gram-negative bacteria that may demonstrate resistance to older antibiotic classes. Marbofloxacin is indicated for treating bacterial infections caused by susceptible organisms. The medicine’s primary function is to resolve conditions caused by sensitive bacteria.

Composition and Physical Forms

The therapeutic action of Mafloxin is based on its single active ingredient, Marbofloxacin, which is prepared in two primary high-level physical forms: as oral tablets and as an injectable aqueous solution. The formulation as an aqueous solution facilitates parenteral administration, which is clinically favored when rapid systemic action or complete absorption is required. Marbofloxacin is characterized by specific chemical structures and properties. This dual availability provides a key differentiating factor, enabling flexible treatment strategies compared to drugs available only in a single form.

Function and General Purpose

The general purpose of Mafloxin is the effective elimination of bacterial infections through a bactericidal mechanism. This means that Marbofloxacin is designed to actively and irreversibly kill susceptible bacteria, rather than merely slowing their growth (bacteriostatic action). This potent mechanism targets key bacterial enzymes essential for DNA function and is integral to the drug's role in the resolution of systemic or localized bacterial diseases.

What side effects are possible with Mafloxin?

Mafloxin is associated with disabling and potentially irreversible serious adverse reactions involving multiple body systems, which has led to significant regulatory restrictions on its use. The U.S. Food and Drug Administration (FDA) mandates a Boxed Warning for the most severe risks.

Serious and Disabling Adverse Reactions

Regulatory agencies, including the FDA and the European Medicines Agency (EMA), have highlighted the risk of serious side effects that can occur within hours to weeks and may be long-lasting (months or years) or permanent. These include:

  • Tendinitis and Tendon Rupture: Risk of tendon damage (most commonly the Achilles tendon), especially increased in the elderly, patients with kidney impairment, those who have received an organ transplant, or those taking systemic corticosteroids.
  • Peripheral Neuropathy: Nerve damage symptoms such as pain, burning, tingling, numbness, or weakness in the arms or legs.
  • Central Nervous System (CNS) Effects: Adverse reactions such as seizures, tremors, confusion, depression, anxiety, insomnia, or hallucinations.
  • Exacerbation of Myasthenia Gravis: Use is contraindicated in patients with a known history of this condition as it may worsen muscle weakness, potentially leading to respiratory failure.

Other Clinically Significant Risks

Other serious documented risks include QT interval prolongation (a heart rhythm disorder), Aortic Aneurysm/Dissection, Hypoglycemia (low blood sugar, sometimes resulting in coma), severe Hypersensitivity Reactions (e.g., Anaphylaxis), and Clostridium difficile-associated diarrhea.

Restrictions and Safety Notes

Mafloxin is reserved for use in patients who have no alternative treatment options for certain infections (e.g., acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis). The regulatory safety framework mandates that treatment must be discontinued immediately at the first sign of any serious adverse reaction, such as tendon pain or symptoms of neuropathy, to prevent the development of potentially irreversible effects.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented clinical manifestations and the emergency actions mandated by regulatory authorities for an overdose of Marbofloxacin (Mafloxin).


Documented Overdose Manifestations

Overdose is officially documented to present primarily with symptoms related to Central Nervous System (CNS) excitation. The most severe manifestation listed in regulatory information is the occurrence of convulsions (seizures). Other documented clinical signs of exposure exceeding the intended therapeutic dose include vomiting, salivation, and inappetence.


Required Emergency Actions

The presentation of severe signs, such as convulsions or any pronounced systemic reaction, requires that patients seek immediate medical attention. Regulators mandate that emergency services should be contacted immediately in severe or life-threatening scenarios.

Management Procedure Official Regulatory Statement
Antidote Availability No specific antidote is known for this overdose.
Treatment Focus Management is described as strictly symptomatic and supportive.
Observation Requirement Hospital monitoring may be required to observe for and promptly manage the development of severe symptoms.

Population-Specific Overdose Note

Official labeling includes the consideration that patients with pre-existing renal impairment may be at an increased risk for severe adverse effects, including enhanced systemic toxicity, due to the drug's primary route of elimination.

Therapeutic Uses of Mafloxin

What Mafloxin Treats: Main Uses and Benefits

Mafloxin is a prescription-only fluoroquinolone antibiotic that is relevant for easing symptoms related to bacterial infection in conditions involving systemic or localized discomfort that may present a challenge in management. Its use is typically reserved for clinical conditions that have responded poorly, or are expected to respond poorly, to other classes of antimicrobials.

Mafloxin is commonly used across domains where additional symptomatic support is needed, primarily addressing conditions involving inflammatory or irritative processes in the skin and soft tissues (like pyoderma and abscesses), complicated urogenital conditions (including severe mastitis and UTIs), and acute bacterial respiratory disease. The medication is applicable within clinical settings that involve acute or disruptive symptom patterns, particularly for managing symptom clusters that may become intense or disruptive.

Therapeutic Focus and Benefits

When used during phases of increased distress or discomfort, Mafloxin supports general well-being during symptomatic phases and may assist with maintaining functional stability. It provides supportive relief when symptoms interfere with routine activities, and may assist with easing the overall symptom load.

Quick Fact: Relief for Persistent Infections
Mafloxin is relevant for managing conditions characterized by periods of heightened symptoms where symptoms create noticeable physiological strain, provides supportive relief that may help patients cope more steadily.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Mafloxin (Moxifloxacin)

Official regulatory documents strictly define the patient populations eligible for systemic Mafloxin use, primarily limiting it to adults 18 years of age and older.

Contraindications (Must NOT Use):

Condition / Population Status
Hypersensitivity to moxifloxacin or any quinolone Contraindicated
Pregnancy or Lactation (Breastfeeding) Contraindicated / Not Recommended
Patients under 18 years of age (Systemic use) Contraindicated / Not Established
Known QT prolongation or uncorrected hypokalemia Contraindicated
History of tendon disorder related to quinolone use Contraindicated
Severe hepatic impairment (Child-Pugh C) Contraindicated
Known Myasthenia Gravis Avoided / Contraindicated

Restricted or Conditional Use:

Use requires special caution and monitoring in older patients (ge 60 years), particularly those taking corticosteroids, due to an increased risk of tendon disorders. Patients with diabetes or CNS conditions like epilepsy should also use the medicine with caution. No dosage adjustment is generally required for renal impairment, but cardiac monitoring may be advised for those with severe hepatic impairment who are otherwise eligible.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Mafloxin (Moxifloxacin) interactions with other substances are classified based on the risk and mechanistic basis, as documented in official prescribing information.

Contraindicated Combinations

Co-administration is strictly contraindicated with other medicinal products known to prolong the QT interval, including Class IA and Class III antiarrhythmics. This restriction is based on the significant increase in the risk of serious ventricular arrhythmias.


Clinically Significant Interactions

Absorption Interference (Chelation)

Products containing multivalent cations (e.g., antacids with aluminum or magnesium, iron, and zinc supplements) form non-absorbable chelate complexes with Mafloxin in the gastrointestinal tract. This interaction critically reduces Mafloxin's systemic absorption and effectiveness. To mitigate this effect, Mafloxin must be administered at least 4 hours before or 8 hours after these cation-containing agents.

Pharmacodynamic Risks

Concomitant use of systemic corticosteroids or Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) increases specific adverse risks. Corticosteroids elevate the risk of tendon disorders (tendinopathy and tendon rupture), while NSAIDs may increase the risk of CNS excitability (e.g., convulsions).

Metabolic Pathway

Mafloxin is generally documented to be not metabolized by or significantly affect the activity of the major cytochrome P-450 (CYP) enzyme system. Therefore, Mafloxin is unlikely to cause clinically relevant pharmacokinetic interactions with drugs metabolized via this pathway.

Mechanism of Action

How Mafloxin Works

Mafloxin exerts its function by targeting distinct enzymatic and cellular processes, operating entirely within the biochemical domain.

Enzymatic Pathway Inhibition

Mafloxin acts within domains involving key enzyme-mediated signaling, primarily targeting essential bacterial enzymes like DNA gyrase and topoisomerase IV. It operates by binding to and stabilizing the DNA-enzyme cleavage complex, which mechanically prevents the required supercoiling, unwinding, and repair functions of the bacterial DNA, thereby modifying early molecular steps.

Intracellular Cascade Effect

This domain covers the downstream molecular effects resulting from the enzyme stabilization event. The modification of these early molecular steps leads to the irreversible cessation of DNA synthesis and transcription within the target cells. This process initiates a molecular sequence that results in the breakdown of the nucleic acid structure and subsequent changes in cellular activity.

Dosage and Administration Information

Mafloxin is administered via either the oral route using tablets or parenterally through an injectable aqueous solution, utilizing intramuscular (IM), subcutaneous (SC), or, for specific indications, intravenous (IV) injection. The administration pattern across all approved forms is a once-daily (q 24 h) regimen.

Dosage is determined by body weight, with the primary standard established as 2 mg per kilogram (2 mg/kg) of body weight. An alternative range exists for the oral form, specified as 1.25 mg/lb to 2.5 mg/lb.

The total duration of use is established according to defined time ranges. While treatment generally lasts a minimum of five days, the course length may extend up to 28 days for urinary tract infections or up to 40 days for certain skin and soft tissue infections.

Specific instructions guide the administration context. For oral intake, the drug should not be co-administered with products containing divalent or trivalent metallic cations (such as iron, calcium, or magnesium), as this can reduce absorption. Use in juvenile subjects is restricted due to potential effects on cartilage, and use in pregnant or lactating subjects requires a prior benefit/risk assessment. For parenteral administration, the total dose may necessitate splitting into multiple injections to adhere to the maximum permissible volume per injection site.

Recent Clinical Evidence

Research evidence / Overview of studies for Mafloxin

Evidence for Use in Skin and Soft Tissue Infections

This section will summarize the types of randomized controlled trials (RCTs) and non-interventional studies that have examined Mafloxin for this condition, detailing the measurement tools used to evaluate the achievement of microbiological outcomes and symptom evolution.

Research was studied for conditions associated with acute or disruptive episodes in the skin and underlying soft tissues. The primary evidence base consists of short-term, randomized controlled trials (RCTs) and various prospective observational studies. These studies examined adult populations diagnosed with infections that presented with cycles of stability and flare-ups. The research focused on outcomes linked to inflammatory or irritative states and monitored microbiological outcomes (bacterial status).

Evidence for Use in Complicated Urogenital Conditions

This part outlines the structure of the evidence base, including the comparative studies and retrospective data, and explains how researchers evaluated the microbiological outcomes and measures of condition stability.

Mafloxin was evaluated in trials for complicated urogenital conditions, including systematic reviews of trials. The goal of this research was to evaluate Mafloxin against both placebo and active comparators in populations often focused on older adults with recurrent conditions. Studies monitored endpoints related to systemic or functional imbalance, primarily the measurement of urine culture testing for bacterial status and the time to measurement of acute symptom changes.

Long-Term Studies and Follow-up

The majority of published evidence for Mafloxin was studied for short-term or episodic symptom patterns, and follow-up durations were limited. Researchers explored short-term symptom changes and often tracked patient status for only a few weeks following the end of treatment. Long-term effects are not fully established, and research focusing on measurement beyond the acute phase is sparse.

What Is Still Uncertain About Mafloxin

The comprehensive evidence landscape highlights several areas where certainty remains low. Evidence quality varies across studies, and some trial findings were mixed. Comparative evidence is lacking against many newer antibiotic treatments. Furthermore, the limited long-term follow-up means that the research does not determine whether an individual will respond similarly over extended periods. Studies help show what has been observed so far, but additional, focused research is ongoing to better understand the observed patterns.

Frequently Asked Questions (FAQ)

Common questions about Mafloxin (FAQ)

Q: How quickly does Mafloxin start working?

Mafloxin is generally absorbed quickly into the body after it is taken. However, official regulatory sources do not state a specific time for when a person should expect to feel relief. Clinical studies evaluate the medicine's success based on defined outcomes like clearance of bacteria over the full treatment course, not a specific time for subjective improvement.

Q: How long after starting Mafloxin should I expect to feel better?

Clinical trials measure how well the medicine works based on specific clinical and microbiological outcomes at the completion of therapy. Official patient information often underscores the importance of taking the medicine for the full course, even when symptoms begin to improve. The course length depends strictly on the type of infection being addressed.

Q: What foods or drinks should people generally avoid while using Mafloxin?

Official information advises against taking Mafloxin with products that contain multivalent cations, such as iron, calcium, or magnesium, as these can significantly reduce the amount of medicine absorbed. Patient guides explicitly name milk and other dairy products as a source of calcium, and recommend separating the intake of these products by several hours.

Q: What happens if a dose of Mafloxin is missed?

Patient instructions indicate that if a dose is forgotten, it should be taken as soon as it is remembered. Regulatory information indicates the dose should not exceed one dose in a single day. Adherence to the prescribed dosing schedule is cited in official information as being necessary for treatment success.

Q: Why is it important to finish the full course of Mafloxin?

Official patient information explains that completing the full prescribed course is necessary to ensure the elimination of all susceptible bacteria causing the infection. This practice is cited in official documents as being important to lessen the risk of bacteria developing resistance to the medicine.

Q: Can Mafloxin affect driving or operating machinery?

Official warnings note that Mafloxin can cause certain side effects, such as dizziness, lightheadedness, or blurred vision. These effects may impact a person's ability to drive or safely operate complex machinery. Patients are advised in the product label to be aware of how the medicine affects them before engaging in these activities.

Q: Can Mafloxin affect blood sugar levels?

Yes, regulatory documents include warnings about the potential for Mafloxin to cause disturbances in blood sugar levels. This can manifest as either low blood sugar (hypoglycemia) or high blood sugar (hyperglycemia), which is a particular concern for patients who have diabetes.

Q: How should people handle a common side effect like nausea from Mafloxin?

Nausea is listed among the most common reported side effects. Patient information may mention that taking the tablet with food could help if stomach upset occurs. Any severe or persistent side effects, including nausea, should be reported.

Q: Do studies support the long-term safety profile of Mafloxin?

Regulatory agencies have noted that the safety profile for long-term use is not fully established. The medicine is associated with risks of serious, disabling, and potentially long-lasting or irreversible adverse reactions. Its use is subject to specific regulatory restrictions, particularly for certain infections when no alternative treatments are available.

Q: Can Mafloxin cause changes in mood or anxiety?

Yes, official safety warnings include potential Central Nervous System (CNS) effects. These adverse reactions can involve changes such as anxiety, depression, insomnia, and hallucinations. These are documented in the regulatory safety updates for the medicine.

Q: Does Mafloxin make you sensitive to the sun?

Yes, official regulatory documents contain warnings about the potential for photosensitivity (phototoxicity). Exposure to sunlight or UV light is advised to be limited as a precaution, as it may result in exaggerated sunburn reactions, such as severe burning or blistering.

Q: Why is Mafloxin sometimes preferred over other drugs for certain uses?

Official documents do not express preference, but indicate the medicine is effective against specific susceptible bacteria. Furthermore, regulatory agencies advise reserving its use for certain non-severe infections only in patients who have no available alternative treatment options.

Q: What is the typical length of time people take Mafloxin?

The required duration of use is prescribed based on the specific type of infection being treated. Official dosage information provides a range for treatment duration, but the exact length must be taken exactly as determined by the prescriber for the condition being addressed.

Q: Are there any long-term side effects associated with Mafloxin use?

Official safety alerts refer to the risk of disabling and potentially long-lasting or permanent adverse reactions. These may affect various body systems, including peripheral neuropathy (nerve damage) and tendon damage.

Q: Does Mafloxin interact with common pain relievers?

Regulatory warnings specifically indicate that co-administration with NSAIDs (a class of pain relievers) may increase the risk of CNS excitability. However, many common non-NSAID pain relievers, such as Acetaminophen, are generally found to have no significant interaction risk with Mafloxin.

Q: Can I take Mafloxin if I am also taking vitamins or herbal supplements?

Vitamins containing multivalent cations (e.g., iron, calcium, magnesium, zinc) must be separated from Mafloxin by several hours to prevent reduced absorption. The safety and effect of specific herbal supplements are typically not assessed in official drug labeling and should be considered with caution.

Q: Is it true that Mafloxin interacts with caffeine?

Official drug labels for Mafloxin do not typically list caffeine as a specific drug-drug interaction. However, some other medicines in the same drug class are known to affect how the body processes caffeine.

Q: Is Mafloxin effective against viral infections?

Mafloxin is officially classified as an antibacterial agent, or an antibiotic. Patient information explicitly confirms that the medicine works against bacteria and is not effective for treating viral infections, such as the common cold or flu.

Q: Is Mafloxin available over the counter in any country?

In major regulatory regions, Mafloxin is officially classified as a prescription-only antibacterial agent. The systemic form of the medicine is not available over the counter in these areas.

Q: How does the body generally process and eliminate Mafloxin?

The body primarily processes the medicine through a chemical change called conjugation, without significant reliance on the major CYP enzyme system. It is then eliminated from the body as unchanged drug through both the urine and the feces.

Q: Is Mafloxin known to interact with dairy products?

Yes, official patient information advises separating the medicine from dairy products, like milk. Dairy products contain calcium, which is a multivalent cation that can bind to Mafloxin and significantly reduce its absorption into the bloodstream.

Q: Why is monitoring sometimes required when taking Mafloxin?

Monitoring may be required due to the risk of serious side effects, including the potential for QT interval prolongation (a heart rhythm disorder). Monitoring may also be advised for high-risk patients, such as those with diabetes, due to the possibility of blood glucose disturbances.

Q: Are there specific patient groups where Mafloxin is generally avoided?

Yes, official warnings list specific patient populations for whom the medicine is generally avoided or requires extreme caution. These include children under 18, patients with a history of tendon disorder, those with Myasthenia Gravis, and patients concurrently taking systemic corticosteroids.

How should Mafloxin be stored and disposed of?

How to Store and Dispose of Mafloxin

Mafloxin (Marbofloxacin) must be stored according to specific regulatory conditions to maintain its labeled quality and stability.

Storage and Stability Constraints

Condition Requirement (Official Labeling)
Temperature Store injectable solution below 25 C.
Prohibition The injectable solution must be protected from freezing.
Protection Keep the product in the original package and protect the injectable solution from light.
In-Use Stability Discard the injectable solution 28 days after first opening the vial.

Child Safety and Disposal

All forms of Mafloxin must be kept out of the sight and reach of children.

Disposal of unused or expired product must be done in accordance with local requirements. Official regulatory instructions state that the medicine must not be thrown away into wastewater or household waste due to environmental considerations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mafloxin found in:

A-Z Index: